Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
-
Clinical dosimetry results from Phase 1 studies of Radspherin® in ovarian and colorectal cancer demonstrate absorbed doses to normal organs well below values associated with toxicity risks
-
The results are consistent with the favorable safety profile observed to date and support the further development of Radspherin® for treatment of peritoneal metastases
Oslo, Norway, 11 August 2026 – Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces the publication of clinical dosimetry data for Radspherin® in the Journal of Nuclear Medicine, one of the leading peer-reviewed journals in the field.
